Ipeleng Kgosiemang-Xaba | Oncology | Innovative Research Award

Published on by Health Scientists

Innovative Research Award

Ipeleng Kgosiemang-Xaba
University of the Free State, South Africa
Ipeleng Kgosiemang-Xaba
Affiliation University of the Free State
Country South Africa
Scopus ID 56707418000
Documents 9
Citations 241
h-index 7
Subject Area Oncology
Event Health Scientists Awards

Ipeleng Kgosiemang-Xaba is presented in this academic recognition profile as a researcher associated with oncology and biomedical research at the University of the Free State in South Africa. Her scholarly work includes investigations of Euphorbia species, phytochemicals, antiproliferative activity, nanomaterials, and cancer-related applications. Publications identify research examining plant-derived compounds, toxicity, pharmacological properties, and nanoparticle-based approaches against breast cancer models. This work connects natural-product research with experimental oncology and drug-discovery questions.[1]

Abstract

Ipeleng Kgosiemang-Xaba is presented in this recognition profile as a researcher associated with oncology and biomedical research at the University of the Free State in South Africa. Her scholarly work includes investigations of Euphorbia species, phytochemicals, antiproliferative activity, nanomaterials, and cancer-related applications. Publications identify research examining plant-derived compounds, toxicity, pharmacological properties, and nanoparticle-based approaches against breast cancer models. This work connects natural-product research with experimental oncology and drug-discovery questions. The profile therefore highlights an interdisciplinary trajectory centered on biologically active South African plants, cancer-related mechanisms, and translational opportunities while maintaining a neutral distinction between documented scientific outputs and award recognition.[3]

Keywords

Euphorbia species; cancer; medicinal plants; pharmacological properties; toxicity; secondary metabolites; breast cancer; antiproliferative activity; iron oxide nanoparticles; iron dioxide nanoparticles; natural-product pharmacology; phytochemicals. These terms are aligned particularly with the publication literature addressing Southern African Euphorbia species and experimental anticancer research.[2]

Introduction

Ipeleng Kgosiemang-Xaba’s research profile reflects an interdisciplinary interest in oncology, medicinal plants, pharmacology, and biomedical technology. Her publications address Euphorbia-derived bioactive compounds and experimental anticancer approaches, including nanoparticle systems evaluated against breast cancer cell lines. These themes place natural-product research within a framework of cancer research and translational biomedical investigation.[1]

Research Profile

Ipeleng Kgosiemang-Xaba has published work spanning molecular biology, medicinal plants, phytochemistry, pharmacology, and oncology. Her research includes studies of Euphorbia species and their secondary metabolites, together with experimental investigations of antiproliferative effects and nanoparticle-mediated approaches. The available literature indicates a continuing interest in linking biological resources with therapeutic research questions.[2][3]

Research Contributions

Ipeleng Kgosiemang-Xaba’s contributions include systematic examination of Southern African Euphorbia species, their medicinal uses, toxicity, phytochemical constituents, and reported pharmacological activities. Her research also includes green synthesis of iron-based nanoparticles using Euphorbia tirucalli and evaluation of antiproliferative activity against breast cancer cell lines, thereby connecting plant science with experimental oncology.[2][3]

Publications

Ipeleng Kgosiemang-Xaba is associated with publications addressing Euphorbia pharmacology, anticancer research, nanoparticle synthesis, and molecular biology. A 2025 review in Plants examined medicinal uses, toxicity, secondary metabolites, and pharmacological properties of Southern African Euphorbia species, while a 2023 Journal of Experimental Nanoscience article evaluated iron-based nanoparticles and breast cancer models.[5]

Research Impact

Ipeleng Kgosiemang-Xaba’s research impact can be considered through the relevance of her publications to natural-product pharmacology, cancer biology, and biomedical nanotechnology. Her work contributes evidence on underexplored Southern African plant resources and experimental anticancer strategies. Citation activity and publication visibility provide measurable indicators, while broader clinical significance requires further validation.[3]

Award Suitability

Ipeleng Kgosiemang-Xaba’s documented research themes are compatible with an Innovative Research Award focused on oncology, natural-product discovery, and biomedical technology. Her publications demonstrate research activity involving anticancer constituents, Euphorbia species, phytochemicals, and nanoparticle systems. Award suitability should remain subject to the event’s published formal criteria, independent verification, and comparative assessment.[4]

Conclusion

Ipeleng Kgosiemang-Xaba presents a research profile connecting Southern African medicinal plants with pharmacology, nanotechnology, and oncology. Her publications provide evidence of work on Euphorbia chemistry, toxicity, antiproliferative activity, and cancer-oriented experimental systems. Collectively, these outputs support recognition of an emerging interdisciplinary research direction without implying clinical efficacy beyond published evidence.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Ipeleng Kgosiemang-Xaba, Author ID 56707418000. Scopus.https://www.scopus.com/authid/detail.uri?authorId=56707418000
  2. Kgosiemang, I. K. R., Lefojane, R., Adegoke, A. M., Ogunyemi, O., Mashele, S. S., & Sekhoacha, M. P. (2025). Pharmacological significance, medicinal use, and toxicity of extracted and isolated compounds from Euphorbia species found in Southern Africa: A review. Plants, 14(3), 469.https://doi.org/10.3390/plants14030469
  3. Kgosiemang, I. K. R., Adegoke, A. M., Mashele, S. S., & Sekhoacha, M. P. (2023). Green synthesis of iron oxide and iron dioxide nanoparticles using Euphorbia tirucalli: Characterization and antiproliferative evaluation against three breast cancer cell lines. Journal of Experimental Nanoscience, 18(1), 2276276.https://doi.org/10.1080/17458080.2023.2276276
  4. Parvez, M., Qhanya, L. B., Mthakathi, N. T., Kgosiemang, I. K. R., et al. (2016). Molecular evolutionary dynamics of cytochrome P450 monooxygenases across kingdoms: Special focus on mycobacterial P450s. Scientific Reports, 6, 33099.https://doi.org/10.1038/srep33099
  5. Kgosiemang, I. K. R. (2024). Targeted delivery of iron, cobalt and magnesium nanoparticles incorporating anticancer constituents of Euphorbia species for treatment of breast cancer. Doctor of Health Sciences in Biomedical Technology, Central University of Technology, Free State.https://cutscholar.cut.ac.za/items/e527142e-a8dc-4c94-8eb1-121facf1eff7/full

Niladry Sekhar Ghosh | Oncology | Best Researcher Award

Published on by Health Scientists

Prof. Niladry Sekhar Ghosh | Oncology | Best Researcher Award

Professor | Assam Down Town University, Guwahati | India

Prof. Niladry Sekhar Ghosh is a distinguished researcher and Professor at Assam Down Town University, Guwahati, serving also as Member Secretary of the Board of Studies, with extensive expertise in pharmaceutical sciences, medicinal chemistry, and biomedical research. He earned his B.Pharm. and M.Pharm. degrees from S.C.S College of Pharmacy, R.G.U.H.S Bangalore, graduating with first-class honors, and completed his Ph.D. at Shobhit University in 2020, focusing on the synthesis of bioactive fluoro-benzothiazole derivatives and the biosynthesis of metallic nanoparticles for biological and pharmacological screening. With over 18 years of teaching experience and significant contributions to research, his key areas of interest include drug discovery, medicinal chemistry, nanotechnology-based drug delivery systems, pharmacological evaluation of bioactive compounds, and cancer therapeutics. Prof. Ghosh has authored more than 50 publications in high-impact journals indexed in SCI, Scopus, and ESCI, including studies on cathepsin inhibitors, benzimidazole and indole derivatives as anticancer agents, and green synthesis of nanoparticles. He has been recognized with multiple honors, notably the Young Teacher Awards by SPER in 2016 and 2018, and has secured competitive research grants from SERB-DST, DBT, ICMR, and NCW for innovative projects in pharmaceutical biotechnology and nanomedicine. Additionally, he holds patents for metallic nanoparticle synthesis and biomedical devices. Beyond research, he serves as a resource person, reviewer, and editor for various scientific journals, contributing to the dissemination of knowledge in medicinal chemistry, pharmacology, and nanotechnology. His leadership roles in academic administration and research guidance underscore his commitment to advancing pharmaceutical education and translational research. He has 90 citations from 22 documents with an h-index of 7.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Dubey, A., Ghosh, N. S., & Singh, R. (2022). Zebrafish as an emerging model: An important testing platform for biomedical science.

2. Dubey, A., Ghosh, N. S., Gupta, A., & Singh, S. (2023). A review on current epidemiology and molecular studies of lumpy skin disease virus—An emerging worldwide threat to domestic animals.

3. Dubey, A., Ghosh, N. S., Agnihotri, N., Kumar, A., Pandey, M., & Nishad, S. (2022). Herbs derived bioactive compounds and their potential for the treatment of neurological disorders.

4. Dubey, A., Ghosh, N. S., Rathor, V. P. S., Patel, S., Patel, B., & Purohit, D. (2022). SARS-CoV-2 infection leads to neurodegenerative or neuropsychiatric diseases.

5. Chandra, D., Yadav, I. K., Jaiswal, D., Ghosh, N., Singh, H. P., Mishra, A., … (Year not specified). Formulation and evaluation of satranidazole microspheres for colon-targeted drug delivery.

Nayeralsadat Fatemi | Oncology | Best Researcher Award

Published on by Health Scientists

Dr. Nayeralsadat Fatemi | Oncology | Best Researcher Award 

Researcher | Research Institute for Gastroenterology and Liver Diseases | Iran

Dr. Nayeralsadat Fatemi is a distinguished Research Scientist at the Research Institute for Gastroenterology and Liver Diseases (RIGLD), Tehran, Iran, with a profound background in genetics and molecular medicine. She obtained her B.Sc. in Genetics from Esfahan University in 2007, followed by an M.Sc. in Genetics from Shahrekord University in 2012, and earned her Ph.D. in Molecular Medicine from Zanjan University of Medical Sciences in 2020. Dr. Fatemi’s research primarily focuses on colorectal cancer, gastrointestinal disorders, reproductive genetics, and the interplay between microbiota and cancer-related molecular pathways. Her work integrates genomics, transcriptomics, and bioinformatics analyses to uncover biomarkers, drug resistance mechanisms, and potential therapeutic targets. She has contributed to over thirty peer-reviewed publications in high-impact journals, including Gut Pathogens, Virulence, Expert Reviews in Molecular Medicine, Digestive Diseases and Sciences, and International Journal of Cancer, with notable studies on Fusobacterium nucleatum in colorectal cancer, microRNA-mediated regulatory networks, and genetic causes of recurrent pregnancy loss. Dr. Fatemi has presented her findings at numerous national and international conferences, earning recognition for excellence in research communication, including Best Poster awards at reproductive medicine congresses. Beyond her research contributions, she serves as an active reviewer and editorial board member for several scientific journals in molecular medicine, cancer biology, and reproductive genetics, reflecting her commitment to advancing scientific rigor and knowledge dissemination in health sciences. Her career exemplifies a dedication to translational research, bridging fundamental molecular discoveries with clinical applications to improve diagnostics, therapeutics, and patient outcomes in gastroenterology and reproductive medicine. She has 218 citations from 31 documents with an h-index of 7.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Fatemi, N., Tierling, S., Es, H. A., Varkiani, M., Mojarad, E. N., Aghdaei, H. A., … (2022). DNA methylation biomarkers in colorectal cancer: Clinical applications for precision medicine.

2. Fatemi, N., Sanati, M. H., Shamsara, M., Moayer, F., Zavarehei, M. J., Pouya, A., … (2014). TBHP-induced oxidative stress alters microRNAs expression in mouse testis. Journal of Assisted Reproduction and Genetics.

3. Amiri Yekta, A., Dalman, A., Eftekhari-Yazdi, P., Sanati, M. H., Shahverdi, A. H., … (2013). Production of transgenic goats expressing human coagulation factor IX in the mammary glands after nuclear transfer using transfected fetal fibroblast cells.

4. Fatemi, N., Sanati, M. H., Jamali Zavarehei, M., Ayat, H., Esmaeili, V., … (2013). Effect of tertiary‐butyl hydroperoxide (TBHP)‐induced oxidative stress on mice sperm quality and testis histopathology.

5. Rejali, L., Seifollahi Asl, R., Sanjabi, F., Fatemi, N., Asadzadeh Aghdaei, H., … (2023). Principles of molecular utility for CMS classification in colorectal cancer management.

Virginie Guastella | Oncology | Best Researcher Award

Published on by Health Scientists

Prof. Dr. Virginie Guastella | Oncology | Best Researcher Award

Associate Professor | University Hospital Clermont-ferrand | France

Dr. Virginie Guastella is a distinguished physician and researcher specializing in palliative care and pain management. She holds a Doctorate in Medicine and an Habilitation à Diriger des Recherches (HDR) focused on opioid analgesics and cancer pain. She currently serves as Head of the Palliative Care Unit at CHU Clermont-Ferrand and as Associate Professor in Palliative Medicine at the University Clermont Auvergne, leading the UIC “Douleur, qualité de vie et maladie grave” within the GRUIC “Douleurs chroniques et thérapeutiques.” Her clinical work emphasizes optimizing pain management, end-of-life care, and therapeutic support for patients with advanced illness, while her research explores critical areas including opioid misuse, the integration of virtual reality and music care in palliative settings, and early detection of chemotherapy-induced neuropathies. She has supervised over 24 medical theses and numerous master-level projects, contributing significantly to clinical education, and is a prolific author with 20 international peer-reviewed publications, multiple national articles, and several book chapters addressing topics from opioid prescribing practices to patient and caregiver experiences in palliative care. Beyond research and clinical responsibilities, she actively participates in national and regional committees, contributes to guideline development, and advocates for palliative medicine education and ethics. Through her combined contributions in research, education, and clinical practice, she has played a pivotal role in advancing patient-centered care, promoting evidence-based practices, and improving the quality of life for patients facing serious illness, establishing herself as a leading figure in palliative care and pain management. She has 485 citations from 41 documents with an h-index of 9.

Profiles: Scopus | ORCID

Featured Publications

1. Lawton, G., Calvel, L., Perceau-Chambard, E., Guastella, V., Economos, G., & Evin, A. (2025). Career trajectories after palliative care training: A national e-survey of medical interns in France.

2. Klaeyle, D., Calvel, L., Perceau-Chambard, E., Guastella, V., Economos, G., & Evin, A. (2025). Teaching palliative medicine in the medical school clerkship in France: A national e-survey.

3. Guastella, V., Lambert, C., Lafforgue, A., Metretin, P., Verstreate, A., Watelet, S., Perceau-Chambard, É., & Lautrette, A. (2024). Withholding or withdrawing life-sustaining treatments in the COVID-19 pandemic.

4. Guastella, V., Delorme, J., Chenaf, C., & Authier, N. (2022). The prevalence of off-label prescribing of transmucosal immediate-release fentanyl in France. Journal of Pain and Symptom Management.

5. Preux, C., Bertin, M., Tarot, A., Authier, N., Pinol, N., Brugnon, D., Pereira, B., & Guastella, V. (2022). Prevalence of opioid use disorder among patients with cancer-related pain: A systematic review.